Log in to save to my catalogue

Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy

Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1717497750

Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy

Publication information

Publisher

United States: Oxford University Press

More information

Scope and Contents

Contents

Background. The use of raltegravir in human immunodeficiency virus (HIV)–infected pregnant women is important in the prevention of mother-to-child HIV transmission, especially in circumstances when a rapid decline of HIV RNA load is warranted or when preferred antiretroviral agents cannot be used. Physiological changes during pregnancy can reduce a...

Alternative Titles

Full title

Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1717497750

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1717497750

Other Identifiers

ISSN

1058-4838

E-ISSN

1537-6591

DOI

10.1093/cid/civ366

How to access this item